Question · Q1 2026
Aman Gupta from Goldman Sachs asked about the relative interest in Cerence's xUI and AI products from Western versus Chinese OEMs for overseas markets, inquiring about potential differences in time-to-market and PPU expectations for these new deals. He also questioned why the full-year adjusted EBITDA guidance was maintained despite exceeding Q1 expectations.
Answer
CEO Brian Krzanich stated that 3 of 5 xUI deals are with Western/classic OEMs, with strong ongoing interest, and time-to-market is accelerating for Western OEMs. He reiterated that xUI deal PPUs are significantly higher than the current run rate of around $5.05. CFO Tony Rodriquez explained that the Q1 adjusted EBITDA beat was due to better legal costs and deferred R&D expenses, providing confidence in the full-year guidance without an immediate change.
Ask follow-up questions
Fintool can predict
CRNC's earnings beat/miss a week before the call